文献速递白血病

纳米颗粒介导靶向t(8;21)阳性急性髓系白血病中的融合基因RUNX1/ETO

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.
PubMed 文献 · Leukemia · 2023-02-23

本文描述使用负载siRNA的脂质纳米颗粒(siRNA-LNPs)特异性靶向白血病融合基因RUNX1/ETO。在t(8;21)-AML小鼠模型中,瞬时敲低RUNX1/ETO可减少其与靶基因结合、改变RUNX1与CBFβ结合,并显著延长中位生存期,同时产生持久的白血病增殖抑制、克隆形成抑制、髓系分化诱导及再植入潜能受损。数据表明暂时性抑制RUNX1/ETO可长期限制白血病自我更新,支持进一步开发siRNA-LNPs治疗融合基因驱动的恶性肿瘤。

要点

  • 负载siRNA的脂质纳米颗粒可特异性靶向白血病融合基因RUNX1/ETO。
  • 瞬时敲低RUNX1/ETO在t(8;21)-AML小鼠模型中显著延长中位生存期。
  • 体内瞬时敲低导致持久的白血病增殖与克隆形成抑制、髓系分化诱导及再植入潜能受损。

核心结论

  • 数据强烈提示暂时性抑制RUNX1/ETO可长期限制白血病自我更新。
  • 结果证明在临床前环境中靶向RUNX1/ETO的可行性,并支持进一步开发siRNA-LNPs用于治疗融合基因驱动的恶性肿瘤。

研究设计与样本

  • 临床前研究,使用负载siRNA的脂质纳米颗粒(siRNA-LNPs)在t(8;21)-AML小鼠模型中进行体内靶向RUNX1/ETO的实验。

主要发现

  • 瞬时敲低RUNX1/ETO减少其与靶基因结合并改变RUNX1及其辅因子CBFβ的结合。
  • 体内转录组变化与t(8;21)-AML小鼠模型中位生存期显著增加相关。
  • 体内瞬时敲低导致持久的白血病增殖与克隆形成抑制、髓系分化诱导及体内再植入潜能显著受损。

临床怎么用

  • 原文结论支持进一步开发siRNA-LNPs用于治疗融合基因驱动的恶性肿瘤,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A hallmark of acute myeloid leukaemias (AMLs) are chromosomal rearrangements that give rise to novel leukaemia-specific fusion genes. Most of these fusion genes are both initiating and driving events in AML and therefore constitute ideal therapeutic targets but are challenging to target by conventional drug development. siRNAs are frequently used for the specific suppression of fusion gene expression but require special formulations for efficient in vivo delivery. Here we describe the use of siRNA-loaded lipid nanoparticles for the specific therapeutic targeting of the leukaemic fusion gene RUNX1/ETO. Transient knockdown of RUNX1/ETO reduces its binding to its target genes and alters the binding of RUNX1 and its co-factor CBFβ. Transcriptomic changes in vivo were associated with substantially increased median survival of a t(8;21)-AML mouse model. Importantly, transient knockdown in vivo causes long-lasting inhibition of leukaemic proliferation and clonogenicity, induction of myeloid differentiation and a markedly impaired re-engraftment potential in vivo. These data strongly suggest that temporary inhibition of RUNX1/ETO results in long-term restriction of leukaemic self-renewal. Our results provide proof for the feasibility of targeting RUNX1/ETO in a pre-clinical setting and support the further development of siRNA-LNPs for the treatment of fusion gene-driven malignancies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Issa H, Swart LE, Rasouli M, et al. Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia. Leukemia. 2023. PMID: 36823395. doi:10.1038/s41375-023-01854-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。